Guerbet_email

 
Guerbet
How can Real World Evidence (RWE)
guide your clinical practice?
Real World Evidence (RWE) is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD (Real World Data). RWE can be generated by different study designs or analyses, including but not limited to randomized trials, including large simple trials, pragmatic trials, and observational studies (prospective and/or retrospective). RWE complements clinical trial data by providing insights that trials can't. This combination could guide your diagnosis decision on what works best on specific patient populations.
Backed by Guerbet's continuous commitment to the field of contrast media, Xenetix® provides you with a large panel of Real World Evidence (RWE)1·5 to help advance your real-world imaging. Its good safety profile has been demonstrated in the general population based on five postmarketing surveillance studies totaling more than 400,000 patients1·5.
Discover more about the real world evidence behind Xenetix
Product information
Sources and references
1. Petersein J., et al., Results of the safety and efficacy of iobitridol in more than 61,000 patients. Eur Radiol, 2003. 13(8): p. 2006- 2011. Methodology: 61,754 patients undergoing routine examination (CT, IVU, OSA, conventional angiography and phlebography). Patients aged from a few weeks to 97 years.
2. Vogl T.J., et al., Safety of iob itridol in the general population and at-risk patients. Eur Radiol, 2006. 16(6): p. 1288-1297. Methodology: 52,057 patients undergoing routin e examination (CT, IVU, OSA, conventional ang iography and phlebography). Patients aged from 4 to 98 years with 72 patients less than 15 years of age and 28549 patients aged 60 and above. Pre-existing risk factors were present in 27% of patients.
3. Wendt-Nordahl G., et al., Intravenous contrast media in uroradiology: Evaluation of safety and tolerability in almost 50,000 patients. Med Princ Pract, 2006. 15(5): p. 358-361. Methodology: 49,975 patients undergoing IVU (98 %) or other urological examinations (2 %). Patients aged from 3 to 101 years. Patients were considered at high risk for 7.4% of the total recruitment.
4. Maurer M., et al., Safety and tolerability of iobitridol in general and in patients with risk factors: results in more than 160,000 patients. Eur J Radiol, 2011. 80: p. 357-62. Methodology: 160,639 patients undergoing routine examination (IVU, CT). Patients aged from 5 to 97 years. At least one risk factor was reported in 2 1 .8% of patients.
5. Gorodetski B., et al., Safety Analysis of Iobitridol as a Nonionic Contrast Medium: A Postmarketing Multicenter Surveillance Study With 94,960 Patients Almost 20 Years After Introduction. Invest Radiol, 2020. 55(3): p. 144-152. Methodology: 94,960 patients undergoing routine examination (CT, IVU, phlebography, angiography, and angiocard iography). At least one risk factor was reported in 30.8% of patients.
Guerbet
Guerbet.com Legal info Contact us
Twitter YouTube Instagram LinkedIn
P21000864
                                                                 
•  Do not reply to this email as it was sent from an unmonitored account.
 
•  Unsubscribe from the Breaking News.
 
•  Reset your password.
 
•  Contact AuntMinnieEurope.com support.
 
•  AuntMinnieEurope.com Privacy Policy.
 
•  Email sent to: .

AuntMinnieEurope.com, 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA
+1 520-298-1000